Effects of enalapril on the vascular wall in an experimental model of syndrome X

American Journal of Hypertension

Volumn 15, Issue 10 I, 2002, Pages 872-878

  Miatello, Roberto ^a,b   Risler, Norma ^a   Gonzalez, Susana ^a   Castro, Claudia ^a   Rüttler, Mariel ^a   Cruzado, Montserrat ^a  

^a UNIVERSIDAD NACIONAL DE CUYO   (Argentina)

^b FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

Author keywords

Enalapril; Fructose fed rats; Hypertension; Insulin resistance; Nitric oxide; Vascular smooth muscle

Indexed keywords

ANGIOTENSIN; ARGININE; CELL DNA; CITRULLINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FRUCTOSE; KININ; NITRIC OXIDE SYNTHASE; THYMIDINE DERIVATIVE;

AMINO ACID METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTERY ENDOTHELIUM; ARTICLE; BLOOD VESSEL WALL; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; ENZYME ACTIVITY; FETAL CALF SERUM; LONG TERM EXPOSURE; MALE; MESENTERY BLOOD FLOW; METABOLIC SYNDROME X; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; RAT STRAIN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANCE BLOOD VESSEL; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA; BLOOD PRESSURE; CELLS, CULTURED; CORONARY VESSELS; DISEASE MODELS, ANIMAL; ENALAPRIL; FRUCTOSE; MALE; MESENTERIC ARTERIES; METABOLIC SYNDROME X; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, WISTAR;

EID: 0036795698     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(02)02983-7     Document Type: Article

References (40)

1. Reaven GM, Laws A: Insulin resistance, compensatory hyperinsulinemia and coronary heart disease. Diabetologia 1994;37:948-952.
2. Hanefeld M, Leonhardt W: The metabolic syndrome. Dtsch Gesundheitsw W 1981;36:545-551.
3. Kaplan NM: The deadly quartet hyperbody obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989;149:1514-1520.
4. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
5. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362:801-809.
6. Hwang IS, Ho H, Hoffman BB, Reaven GM: Fructose-induced insulin resistance and hypertension in rats. Hypertension 1987;10:512-516.
7. Bell RC, Ryan EA, Finegood DT: Consequences of high dietary fructose in the islet-transplanted rat with suboptimal beta-cell mass. Am J Physiol 1996;270:E292-298.
8. Luo J, Rizkalla SW, Lerer-Metzger M, Boillot J, Ardeleanu A, Bruzzo F, Chevalier A, Slama G: A fructose-rich diet decreases insulin-stimulated glucose incorporation into lipids but not glucose transport in adipocytes of normal and diabetic rats. J Nutr 1995;125:164-171.
9. Richey JM, Si X, Halter JB, Webb RC: Fructose perfusion in rat mesenteric arteries impairs endothelium-dependent vasodilation. Life Sci 1998;62:PL55-PL62.
10. Kashiwagi A, Shinozaki K, Nishio Y, Okamura T, Toda N, Kikkawa R: Free radical production in endothelial cells as a pathogenetic factor for vascular dysfunction in the insulin resistance state. Diab Res Clin Pract 1999;45:199-203.
11. Shinozaki K, Kashiwagi A, Nishio Y, Okamura T, Yoshida Y, Masada M, Toda N, Kikkawa R: Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2- imbalance in insulin-resistant rat aorta. Diabetes 1999;48:2437-2445.
12. Kamata K, Yamashita K: Insulin resistance and impaired endothelium-dependent renal vasodilatation in fructose-fed hypertensive rats. Res Commun Mol Pathol Pharmacol 1999;103:195-210.
13. Miatello R, Risler N, Castro C, Gonzalez S, Ruttler M, Cruzado M: Aortic smooth muscle cell proliferation and endothelial nitric oxide synthase activity in fructose-fed rats. Am J Hypertens 2001;14:1135-1141.
14. Iyer SN, Katovich MJ: Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats. Am J Hypertens 1996;9:662-668.
15. Miatello RM, Damiani MT, Nolly HL: Cardiovascular kinin-generating capability in hypertensive fructose-fed rats. J Hlypertens 1998;16:1273-1277.
16. Giacchetti G, Sechi LA, Griffin CA, Don BR, Mantero F, Schambelan M: The tissue renin-angiotensin system in rats with fructose-induced hypertension: Overexpression of type I angiotensin II receptor in adipose tissue. J Hypertens 2000;18:695-702.
17. Kim S, Iwao H: Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2001;52:11-34.
18. Cruzado M, Risler N, Castro C, Ortiz A, Rüttler M: Proliferative effect of insulin on cultured smooth muscle cells from rat mesenteric resistance vessels. Am J Hypertens 1998;11:54-58.
19. Bredt DS, Snyder SH: Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci U S A 1990;87:682-685.
20. Tooke JE, Hannemann MM: Adverse endothelial function and the insulin resistance syndrome. J Intern Med 2000;247:425-431.
21. Gibbons GH: Vasculoprotective and cardioprotective mechanisms of angiotensin-converting enzyme inhibition: The homeostatic balance between angiotensin II and nitric oxide. Clin Cardiol 1997;20(Supp II):II-18-II-25.
22. Balon TW, Jasman A, Scott S, Meehan WP, Rude RK, Nadler JL: Dietary magnesium prevents fructose-induced insulin insensitivity in rats. Hypertension 1994;23:1036-1039.
23. Resnick LM, Laragh JH, Sealey JE, Alderman MH: Divalent cations in essential hypertension. Relation between serum ionized calcium, magnesium, and plasma renin activity. N Engl J Med 1983;309:888-891.
24. Haenni A, Berglund L, Reneland R, Andersson PE, Lind L, Lithell H: The alterations in insulin sensitivity during angiotensin converting enzyme inhibitor treatment are related to changes in the calcium/magnesium balance. Am J Hypertens 1997;10:145-151.
25. Navarro-Cid J, Maeso R, Perez-Vizcaino F, Cachofeiro V, Ruilope LM, Tamargo J, Lahera V: Effects of losartan on blood pressure, metabolic alterations, and vascular reactivity in the fructose-induced hypertensive rats. Hypertension 1995;26:1074-1078.
26. Clerk A, Gillespie-Brown J, Fuller SJ, Sugden PH: Stimulation of phosphatidylinositol hydrolysis, protein kinase activity translocation and nitrogen-activated protein kinase activity by bradykinin in rat ventricular myocytes: Dissociation from the hypertrophic response. Biochem J 1996;317:109-118.
27. Stearns S, Schlesingh MJ, Rudy A: Incidence and clinical significance of coronary artery disease in diabetes mellitus. Arch Intern Med 1947;80:463-474.
28. Etienne P, Pares-Herbute N, Mnai-Ponset L, Gabrion J, Rabesandranata H, Herbute S, Monnier L: Phenotype modulation in primary cultures of aortic smooth muscle cells from streptozotocin-diabetic rats. Differentiation 1998;63:225-236.
29. Komalavilas P, Shah PK, Jo H, Lincoln TM: Activation of mitogenactivated protein kinase pathways by cyclic GMP and cyclic GMP-dependent protein kinase in contractile vascular smooth muscle cells. J Biol Chem 1999;274:34301-34309.
30. Alipui C, Ramos K, Tenner JE: Alterations of rabbit aortic smooth muscle cell proliferation in diabetes mellitus. Cardiovasc Res 1993;27:1229-1232.
31. De Meyer GR, Herman AG: Nitric oxide and vascular endothelial dysfunction, in Ignarro LJ (ed): Nitric Oxide Biology and Pathobiology. San Diego, Academic, 2000, pp 547-567.
32. Andrès V: Control of vascular smooth muscle cell growth and its implication in atherosclerosis and restenosis. Int J Mol Med 1998;2:81-89.
33. Garg UC, Hassid A: Nitric oxide generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-1777.
34. Cornwell TL, Arnold E, Boerth NJ, Lincoln TM: Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol 1994;267:C1405-C1413.
35. Dubey RK, Jackson EK, Luscher TF: Nitric oxide inhibits angiotensin II-induced migration of rat smooth muscle cell. J Clin Invest 1995;96:141-149.
36. Cayatte AJ, Palacino JJ, Horten K, Cohen RA: Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994;14:753-759.
37. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA: Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coil Cardiol 1996;27:567-574.
38. Bravo R, Somoza B, Ruiz-Gayo M, González C, Ruilope LM, Fernández-Alfonso MS: Differential effect of chronic antihypertensive treatment on vascular smooth muscle cell phenotype in spontaneously hypertensive rats. Hypertension 2001;37:e4-e10.
39. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA: Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitor. Pharmacol Rev 1995;47:25-49.
40. Hornig B, Kohler C, Drexler H: Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997;95:1115-1118.